WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Coyotes players informed the team is expected to move to Salt Lake City, AP source saysQB Kellen Mond joining the New Orleans Saints to compete for a backup roleJalen Green has 26 points and Houston cruises to 116Don Donoher, the winningest basketball coach at Dayton, dies at 92Washington man pleads guilty to groping woman on San Diego to Seattle flightTrump's hush money trial: What to know with jury selection to begin MondayRetiring Chairman Sean McManus leaves CBS Sports with its critical properties locked up longRobert MacNeil, creator of PBS 'NewsHour, dead at 93Retiring Chairman Sean McManus leaves CBS Sports with its critical properties locked up longTrump assails Jewish voters who back Biden: 'Should have their head examined'
2.4479s , 6498.984375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Investigation news portal